SCHEDULE: Venrock Group Cuts Pharvaris Stake to 3.8%
Schedule 13G Amendment
A group of investors led by Venrock Healthcare Capital Partners has reduced its beneficial ownership in Pharvaris N.V. to 3.8% of ordinary shares.
Summary
- A group of reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., collectively hold 2,047,620 ordinary shares of Pharvaris N.V.
- This aggregate ownership represents 3.8% of Pharvaris N.V.'s ordinary shares outstanding.
- The percentage is calculated based on 54,493,142 ordinary shares outstanding as of March 31, 2025, as reported in the Issuer's prospectus supplement dated July 22, 2025.
- The reporting persons, including Nimish Shah and Bong Y. Koh, share both voting and dispositive power over all 2,047,620 beneficially owned shares.
- This filing is an Amendment No. 2 to a previous Schedule 13G, indicating a change in beneficial ownership.
Sentiment
Score: 4
Explanation: The filing indicates a reduction in beneficial ownership by a significant investor group (Venrock Healthcare Capital Partners and related entities) to below the 5% threshold, suggesting a decreased stake in the company.
Negatives
- The reporting group's beneficial ownership in Pharvaris N.V. has decreased to 3.8% of the ordinary shares.
- This amendment indicates that the reporting group, previously a 5% or greater beneficial owner, no longer holds a stake above that threshold.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the reduction in stake by a significant institutional investor as a signal of decreased confidence or a strategic shift by that investor.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date as of which Pharvaris N.V.'s ordinary shares outstanding (54,493,142) were reported. |
| 06/30/2025 | Date of event requiring the filing, reflecting the reported beneficial ownership. |
| 07/22/2025 | Date of the Issuer's prospectus supplement. |
| 07/24/2025 | Date the Issuer's prospectus supplement was filed with the SEC. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Recommendation
holdThe filing primarily discloses a reduction in beneficial ownership by a significant investor group to below 5%. While this indicates a decreased stake, it does not provide new fundamental information about Pharvaris N.V.'s operational performance, financial health, or strategic direction. Investors should consider this ownership change as a data point but await further company-specific disclosures for a comprehensive investment decision.
Keywords
Pharvaris N.V., Venrock Healthcare Capital Partners, Beneficial Ownership, Schedule 13G, Institutional Ownership, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.